https://m2.mtmt.hu/ hun 2026-10-24 21:40 JournalArticle 35789560 VALIDATED true 0 false 2026-09-23T19:00:49.228+0000 2026-09-23T18:59:38.429+0000 2025-02-26T12:01:51.188+0000 true 10002439 Tordai Attila /api/author/10002439 Author Tordai Attila (Orvostudomány) true 10002439 2025-03-19T05:18:47.990+0000 2025-03-12T10:44:48.473+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Józwiak-Hagymásy, Judit true true /api/journal/1220 REVIEWED CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 1040-8428 1879-0461 true false 1220 false 1220 true 1040-8428 1879-0461 Journal FOREIGN 209 104661 104661 9 2025 true 2025 true true true false false NONE 2026-09-23 false 1 0 1 1 0 1 1 1 1 1 1 1 1 1 0 0 1 1 1 1 0 1 1 Folyóiratcikk Journal Article 24 1 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2025 0 1 1 1 1 D1 false false false false 2025-03-11T10:44:48.326+0000 Transzfúziológiai Tanszék (SE / AOK / K) 2 9 1 10 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 123525723 /api/authorship/123525723 Józwiak-Hagymásy, Judit 1 0.1 true false false Józwiak-Hagymásy Judit true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 123525724 /api/authorship/123525724 Széles, Ábel 2 0.1 false false false Széles Ábel true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 123525725 /api/authorship/123525725 Dóczi, Tamás 3 0.1 false false false Dóczi Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 123525726 /api/authorship/123525726 Németh, Bertalan [Németh, Bertalan (Egészség-gazdaságtan), szerző] 4 0.1 false false false Author 10053881 /api/author/10053881 Németh Bertalan (Egészség-gazdaságtan) Németh Bertalan true 10053881 true Németh Bertalan true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 123525727 /api/authorship/123525727 Mezei, Dóra 5 0.1 false false false Mezei Dóra true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 123525728 /api/authorship/123525728 Varga, Hédi 6 0.1 false false false Varga Hédi true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 123525729 /api/authorship/123525729 Gronchi, Alessandro 7 0.1 false false false Gronchi Alessandro true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 123525730 /api/authorship/123525730 van Houdt, Winan J. 8 0.1 false false false van Houdt Winan J. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 123525731 /api/authorship/123525731 Tordai, Attila ✉ [Tordai, Attila (Orvostudomány), szerző] Transzfúziológiai Tanszék (SE / AOK / K) 9 0.1 false false true Author 10002439 /api/author/10002439 Tordai Attila (Orvostudomány) Tordai Attila true 10002439 true Tordai Attila true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 123525732 /api/authorship/123525732 Csanádi, Marcell 10 0.1 false true false Csanádi Marcell true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 28481513 /api/publicationidentifier/28481513 DOI: 10.1016/j.critrevonc.2025.104661 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.1016/j.critrevonc.2025.104661 https://doi.org/10.1016/j.critrevonc.2025.104661 false true PublicationIdentifier 28745764 /api/publicationidentifier/28745764 WoS: 001436370400001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001436370400001 https://www.webofscience.com/wos/woscc/full-record/001436370400001 true true PublicationIdentifier 28745753 /api/publicationidentifier/28745753 Scopus: 85218881105 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85218881105 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85218881105 true true PublicationIdentifier 28481675 /api/publicationidentifier/28481675 PubMed: 39986403 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 39986403 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39986403&dopt=Abstract false true SjrRating 11586646 /api/sjrrating/11586646 sjr:D1 (2025) Scopus - Geriatrics and Gerontology CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 1040-8428 1879-0461 8 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2717 /api/classificationexternal/2717 Scopus - Geriatrics and Gerontology true 2717 true D1 DIRECT true true Reference 64184744 /api/reference/64184744 1. Adarkwah 2016: Risk of bias in model-based economic evaluations: the ECOBIAS checklist., Expert Rev Pharmacoecon Outcomes Res, 16, p. 513, DOI: 10.1586/14737167.2015.1103185 1 10.1586/14737167.2015.1103185 false true Reference 64184745 /api/reference/64184745 2. Amdahl 2014: Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom., Sarcoma, 2014, DOI: 10.1155/2014/481071 2 10.1155/2014/481071 false true Reference 64184746 /api/reference/64184746 3. Bonvalot 2020: Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial., The Lancet. Oncology, 21, p. 1366, DOI: 10.1016/S1470-2045(20)30446-0 3 10.1016/S1470-2045(20)30446-0 false true Reference 64184747 /api/reference/64184747 4. Bullement 2019: A review of recent decision-analytic models used to evaluate the economic value of cancer treatments., Appl Health Econ Health Policy, 17, p. 771, DOI: 10.1007/s40258-019-00513-3 4 10.1007/s40258-019-00513-3 false true Reference 64184748 /api/reference/64184748 5. CADTH (2012). "Final Economic Guidance Report - Pazopanib (Votrient) for Soft Tissue Sarcoma." Available at: 〈https://www.cadth.ca/sites/default/files/pcodr/pcodr-votrientsts-fn-egr.pdf〉 5 false true Reference 64184749 /api/reference/64184749 6. CADTH (2016). "Final Economic Guidance Report - Trabectedin for Metastatic Liposarcoma or Leiomyosarcoma." Available at: 〈https://www.cadth.ca/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_fn_egr.pdf〉 6 false true Reference 64184750 /api/reference/64184750 7. CADTH (2018). "Final Economic Guidance Report - Olaratumab (Lartruvo) for Soft Tissue Sarcoma." Available at: 〈https://www.cadth.ca/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_fn_egr.pdf〉 7 false true Reference 64184751 /api/reference/64184751 8. CADTH (2019). "Final Economic Guidance Report - Larotrectinib (Vitrakvi) for Neurotrophic Tyrosine Receptor Kinase (NTRK) Positive Solid Tumours." Available at: 〈https://www.cadth.ca/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_fnEGR_NOREDACT-ABBREV_Post_31Oct2019_final.pdf〉 8 false true Reference 64184752 /api/reference/64184752 9. Carbone 2021: Multidisciplinary Management of Retroperitoneal Sarcoma: Diagnosis, Prognostic Factors and Treatment., Cancers (Basel), 13, p. 4016, DOI: 10.3390/cancers13164016 9 10.3390/cancers13164016 false true Reference 64184753 /api/reference/64184753 10. Chau, Bonny, et al. "Cost-utility analysis of surveillance strategies for soft tissue sarcoma recurrence." (2020): 11565-11565., DOI: 10.1200/JCO.2020.38.15_suppl.11565 10 10.1200/JCO.2020.38.15_suppl.11565 false true Reference 64184754 /api/reference/64184754 11. Danieli 2023: Staging Systems and Nomograms for Soft Tissue Sarcoma., Curr Oncol, 30, p. 3648, DOI: 10.3390/curroncol30040278 11 10.3390/curroncol30040278 false true Reference 64184755 /api/reference/64184755 12. Daupin 2017: Ä medico-economic study of trabectedin compared with end-stage treatment in soft tissue sarcomas., Journal of cancer policy, 12, p. 55, DOI: 10.1016/j.jcpo.2017.03.011 12 10.1016/j.jcpo.2017.03.011 false true Reference 64184756 /api/reference/64184756 13. Del Río-Valencia 2018: Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages., Farmacia Hospitalaria, 42, p. 204 13 false true Reference 64184757 /api/reference/64184757 14. Delea 2014: "Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada., Current Oncology, 21, DOI: 10.3747/co.21.1899 14 10.3747/co.21.1899 false true Reference 64184758 /api/reference/64184758 15. Demetri 2017: Advances and controversies in the management of soft tissue sarcomas., Future Oncol, 13, p. 3, DOI: 10.2217/fon-2016-0498 15 10.2217/fon-2016-0498 false true Reference 64184759 /api/reference/64184759 16. Du 2020: Heterogeneity of Soft Tissue Sarcomas and Its Implications in Targeted Therapy., Front Oncol, 10, DOI: 10.3389/fonc.2020.564852 16 10.3389/fonc.2020.564852 false true Reference 64184760 /api/reference/64184760 17. Fernandez 2017: "Trabectedin Versus Pazopanib within The Treatment of Advanced, Metastatic, Leiomyosarcomas in Scotland: Results of A Cost-Effectiveness Analysis Following A Matching Adjusted Indirect Comparison., Value in Health, 20, p. A427, DOI: 10.1016/j.jval.2017.08.168 17 10.1016/j.jval.2017.08.168 false true Reference 64184761 /api/reference/64184761 18. Fleming 2001: Ütility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas., Cancer, 92, p. 863, DOI: 10.1002/1097-0142(20010815)92:4&lt;863::AID-CNCR1394&gt;3.0.CO;2-E 18 10.1002/1097-0142(20010815)92:4&lt;863::AID-CNCR1394&gt;3.0.CO;2-E false true Reference 64184762 /api/reference/64184762 19. Fuchs B., Boes S. Cost-Effectiveness and Efficiency of Chemotherapy for Soft Tissue Sarcoma. PROSPERO 2024 CRD42024519599 Available from: 〈https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024519599〉 19 false true Reference 64184763 /api/reference/64184763 20. Gronchi 2020: Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups., J Clin Oncol, 38, p. 2178, DOI: 10.1200/JCO.19.03289 20 10.1200/JCO.19.03289 false true Reference 64184764 /api/reference/64184764 21. Gronchi, A., Miah, A.B., Dei Tos et al., Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology. 32(11), 1348–1365. https://doi.org/10.1016/j.annonc.2021.07.006, DOI: 10.1016/j.annonc.2021.07.006 21 10.1016/j.annonc.2021.07.006 false true Reference 64184765 /api/reference/64184765 22. Guest 2013: "Cost Effectiveness of First‐Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden., Sarcoma, 2013 22 false true Reference 64184766 /api/reference/64184766 23. Haddaway, N.R., Grainger, M.J., Gray, C.T. (2021) citationchaser: An R package and Shiny app for forward and backward citations chasing in academic searching. doi: 10.5281/zenodo.4543513. Available at: 〈https://estech.shinyapps.io/citationchaser/〉, DOI: 10.1002/jrsm.1563 23 10.1002/jrsm.1563 false true Reference 64184767 /api/reference/64184767 24. Józwiak-Hagymásy J., Csanádi M., Országh E., Dóczi T. Systematic literature review on the health economic evaluations and models related to retroperitoneal sarcoma. Available from: 〈https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023483406〉 24 false true Reference 64184768 /api/reference/64184768 25. Lambdin 2023: A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2)., Ann Surg Oncol, 30, p. 4573, DOI: 10.1245/s10434-023-13500-9 25 10.1245/s10434-023-13500-9 false true Reference 64184769 /api/reference/64184769 26. Lorenzovici 2023: Systematic Literature Review of Economic Evaluations of Treatment Alternatives in Chronic Lymphocytic Leukemia., BioDrugs, 37, p. 219, DOI: 10.1007/s40259-023-00583-9 26 10.1007/s40259-023-00583-9 false true Reference 64184770 /api/reference/64184770 27. Michaeli, T., Jürges, H., & Michaeli, D.T. (2023). FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis. BMJ (Clinical research ed.), 381, e073242., DOI: 10.1136/bmj-2022-073242 27 10.1136/bmj-2022-073242 false true Reference 64184771 /api/reference/64184771 28. Miller 2012: "CT scans for pulmonary surveillance may be overused in lower-grade sarcoma."., The Iowa orthopaedic journal, 32, p. 28 28 false true Reference 64184772 /api/reference/64184772 29. Miller 2014: Current challenges in health economic modeling of cancer therapies: a research inquiry., Am Health Drug Benefits, 7, p. 153 29 false true Reference 64184773 /api/reference/64184773 30. Nelson 2006: "Cost analysis of functional restoration surgery for extremity soft-tissue sarcoma., Plastic and reconstructive surgery, 117, p. 277, DOI: 10.1097/01.prs.0000187140.83705.cf 30 10.1097/01.prs.0000187140.83705.cf false true Reference 64184774 /api/reference/64184774 31. NICE (2010). "Trabectedin for the treatment of advanced soft tissue sarcoma." Available at: 〈https://www.nice.org.uk/guidance/ta185/resources/trabectedin-for-the-treatment-of-advanced-soft-tissue-sarcoma-pdf-82598497821637〉 31 false true Reference 64184775 /api/reference/64184775 32. Page 2021: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews., BMJ, 372, p. n71, DOI: 10.1136/bmj.n71 32 10.1136/bmj.n71 false true Reference 64184776 /api/reference/64184776 33. Porter 2002: "Cost‐effectiveness of staging computed tomography of the chest in patients with T2 soft tissue sarcomas., Cancer, 94, p. 197, DOI: 10.1002/cncr.10184 33 10.1002/cncr.10184 false true Reference 64184777 /api/reference/64184777 34. Porter 2004: "Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue sarcoma: a combined analysis from the University of Texas MD Anderson and Memorial Sloan-Kettering Cancer Centers., The Journal of Thoracic and Cardiovascular Surgery, 127, p. 1366, DOI: 10.1016/j.jtcvs.2003.11.016 34 10.1016/j.jtcvs.2003.11.016 false true Reference 64184778 /api/reference/64184778 35. Qu 2017: Cost-Effectiveness Analysis of Preoperative Versus Postoperative Radiation Therapy in Extremity Soft Tissue Sarcoma., International journal of radiation oncology, biology, physics, 97, p. 339, DOI: 10.1016/j.ijrobp.2016.10.009 35 10.1016/j.ijrobp.2016.10.009 false true Reference 64184779 /api/reference/64184779 36. Rafia 2013: Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal., PharmacoEconomics, 31, p. 471, DOI: 10.1007/s40273-013-0044-7 36 10.1007/s40273-013-0044-7 false true Reference 64184780 /api/reference/64184780 37. Richard 2016: Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy for Preoperative Treatment of Extremity Soft Tissue Sarcomas., International journal of radiation oncology, biology, physics, 95, p. 999, DOI: 10.1016/j.ijrobp.2016.02.005 37 10.1016/j.ijrobp.2016.02.005 false true Reference 64184781 /api/reference/64184781 38. Roets 2024: Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review., Crit Rev Oncol Hematol, 197, DOI: 10.1016/j.critrevonc.2024.104345 38 10.1016/j.critrevonc.2024.104345 false true Reference 64184782 /api/reference/64184782 39. Royce 2017: "Cost–effectiveness of surveillance for distant recurrence in extremity soft tissue sarcoma., Annals of surgical oncology, 24, p. 3264, DOI: 10.1245/s10434-017-5996-y 39 10.1245/s10434-017-5996-y false true Reference 64184783 /api/reference/64184783 40. Rothermundt 2023: Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022., European journal of cancer, 180, p. 158, DOI: 10.1016/j.ejca.2022.11.008 40 10.1016/j.ejca.2022.11.008 false true Reference 64184784 /api/reference/64184784 41. Salerno 2022: Radiation Therapy for Soft Tissue Sarcoma: Indications, Timing, Benefits, and Consequences., Surg Clin North Am, 102, p. 567, DOI: 10.1016/j.suc.2022.04.001 41 10.1016/j.suc.2022.04.001 false true Reference 64184785 /api/reference/64184785 42. Sbaraglia 2019: The pathology of soft tissue sarcomas., Radiol Med, 124, p. 266, DOI: 10.1007/s11547-018-0882-7 42 10.1007/s11547-018-0882-7 false true Reference 64184786 /api/reference/64184786 43. Simpson 2010: Trabectedin for the treatment of advanced metastatic soft tissue sarcoma., Health technology assessment (Winchester, England), 14, p. 63, DOI: 10.3310/hta14suppl1-09 43 10.3310/hta14suppl1-09 false true Reference 64184787 /api/reference/64184787 44. Soini 2011: "Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information., Annals of Oncology, 22, p. 215, DOI: 10.1093/annonc/mdq339 44 10.1093/annonc/mdq339 false true Reference 64184788 /api/reference/64184788 45. Studdert 2019: Application of pharmacoeconomics to formulary management in a health system setting., American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists, 76, p. 381, DOI: 10.1093/ajhp/zxy010 45 10.1093/ajhp/zxy010 false true Reference 64184789 /api/reference/64184789 46. Tikhonova 2018: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal., PharmacoEconomics, 36, p. 39, DOI: 10.1007/s40273-017-0568-3 46 10.1007/s40273-017-0568-3 false true Reference 64184790 /api/reference/64184790 47. Tong 2019: "MRI screening for uterine leiomyosarcoma., Journal of Magnetic Resonance Imaging, 49, p. e282, DOI: 10.1002/jmri.26630 47 10.1002/jmri.26630 false true Reference 64184791 /api/reference/64184791 48. Verboom 2019: "Survival and Cost‐Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients., Sarcoma, 2019 48 false true Reference 64184792 /api/reference/64184792 49. Veritas Health Innovation, Melbourne, Australia. Available at 〈www.covidence.org〉 [software] 49 false true Reference 64184793 /api/reference/64184793 50. Verschoor 2020: Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study., Clin. Sarcoma Res., 10, p. 18, DOI: 10.1186/s13569-020-00137-5 50 10.1186/s13569-020-00137-5 false true Reference 64184794 /api/reference/64184794 51. Villa 2015: "Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain., Clinical and Translational Oncology, 17, p. 24, DOI: 10.1007/s12094-014-1191-9 51 10.1007/s12094-014-1191-9 false true Reference 64184795 /api/reference/64184795 52. von Mehren 2022: Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology., J Natl Compr Canc Netw, 20, p. 815, DOI: 10.6004/jnccn.2022.0035 52 10.6004/jnccn.2022.0035 false true Reference 64184796 /api/reference/64184796 53. WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed. Vol. 3). 〈https://publications.Iarc.fr/588〉 53 false true Reference 64184797 /api/reference/64184797 54. Zuluaga-Sanchez 2018: "Cost‐Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States., Sarcoma, 2018 54 false true /api/publication/35789560 Józwiak-Hagymásy Judit et al. Economic evaluations and health economic models of soft tissue sarcomas: Systematic literature review from a European and North American perspective. (2025) CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 1040-8428 1879-0461 209<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" >Józwiak-Hagymásy Judit </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Széles Ábel </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Dóczi Tamás </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10053881"><a href="/gui2/?type=authors&mode=browse&sel=10053881" target="_blank">Németh Bertalan (<span class="authorship-author-name">Németh Bertalan</span> <span class="authorAux-mtmt"> Egészség-gazdaságtan</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Mezei Dóra </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Varga Hédi </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Gronchi Alessandro </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >van Houdt Winan J. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10002439"><a href="/gui2/?type=authors&mode=browse&sel=10002439" target="_blank">Tordai Attila ✉ (<span class="authorship-author-name">Tordai Attila</span> <span class="authorAux-mtmt"> Orvostudomány</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Transzfúziológiai Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Csanádi Marcell </span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;35789560" target="_blank">Economic evaluations and health economic models of soft tissue sarcomas: Systematic literature review from a European and North American perspective</a></div> <div> <span class="journal-title">CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/1040-8428">1040-8428</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1879-0461">1879-0461</a>)</span>: <span class="journal-volume">209</span> <span class="page"> Paper 104661. 9 p. </span> <span class="year">(2025)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.1016/j.critrevonc.2025.104661" target="_blank" href="https://doi.org/10.1016/j.critrevonc.2025.104661"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001436370400001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001436370400001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85218881105" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85218881105"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="39986403" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39986403&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Geriatrics and Gerontology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Hematology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Oncology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 1</span> | Független: 1 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 1 | Scopus jelölt:&nbsp;1 | WoS/Scopus jelölt:&nbsp;1 | DOI jelölt:&nbsp;1 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;35789560&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 1 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 35789560</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="lastModified">Utolsó módosítás: 2026.09.23. 20:59 Németh Bertalan (Egészség-gazdaságtan) </div> </div></div>